Pharma's AI Paradox: Universal Adoption Meets Execution Stagnation

The 2025 Commercial and Medical IT landscape survey paints a picture of an industry at a critical inflection point. Although generative AI has moved from a competitive advantage to a standard requirement, internal confidence remains tepid. Respondents rated their innovation confidence at a mere 3 out of 5, citing significant gaps in the operational discipline required to manage regulatory risk and scale digital programs.

Financial and structural hurdles further complicate the transition. Most organizations dedicate less than 25% of their digital budgets to innovation, and two-thirds lack dedicated executive leadership in the form of a Chief Digital or AI Officer. Karl Kraft, President of TGaS Advisors, emphasized that the current era of experimentation must give way to rigorous governance and modernized data foundations to achieve any lasting business impact.

To move beyond the current plateau, Trinity advises leaders to prioritize three areas over the next three years: establishing formal AI governance frameworks, funding measurable initiatives, and securing long-term investments in AI-ready data. Without these shifts, firms face mounting compliance exposure and rising costs. As Brian Voellmecke, Vice President of CMIT Solutions, noted, the next phase of industry transformation will be defined not by the novelty of AI tools, but by the ability to operationalize them responsibly.